THOR Therapeutics is a biopharmaceutical company that utilizes genetic, molecular biology, and computational techniques to develop first-in-class therapeutics targeting orphan and rare diseases. By focusing on novel therapeutic targets, the company aims to provide preclinical candidates, including monoclonal antibodies and anti-sense oligonucleotides, to address unmet medical needs in these underserved patient populations.
Funding
Funding not disclosed
Founders
Product
Problem
Many orphan and rare diseases lack effective treatments due to the challenges in identifying and validating novel therapeutic targets. The limited patient populations and complex underlying biology of these diseases often deter traditional drug development approaches.
Solution
THOR Therapeutics is a biopharmaceutical company focused on developing first-in-class therapeutics for orphan and rare diseases by leveraging genetic, molecular biology, and computational techniques to unlock novel therapeutic targets and mechanisms. The company employs a multidisciplinary approach to generate preclinical candidates, including monoclonal antibodies and anti-sense oligonucleotides, designed to address unmet medical needs in these underserved patient populations. THOR Therapeutics aims to deliver innovative treatments by focusing on mitochondrial energy metabolism and other novel targets relevant to metabolic, immunologic, and oncologic disorders.
Target Audience
The primary target audience includes patients suffering from orphan and rare diseases, as well as healthcare providers and researchers seeking novel therapeutic options for these conditions.
Features
- Utilizes genetic, molecular biology, and computational techniques for target discovery
- Focuses on mitochondrial energy metabolism and other novel targets
- Develops monoclonal antibodies and anti-sense oligonucleotides as therapeutic candidates
- Employs a multidisciplinary approach to drug development